MASLD	metabolic dysfunction-associated steatotic liver disease
CVD	cardiovascular disease
ROS	reactive oxygen species
LDL	low-density lipoprotein
HCC	hepatocellular carcinoma
LDL-C	how-density lipoprotein cholesterol
SAMs	statin-associated muscle symptoms
ASCVD	atherosclerotic cardiovascular disease
MASH	metabolic dysfunction-associated steatohepatitis
NAC	N-acetylcysteine
HSC	hepatic stellate cell
RCT	randomised controlled trial
AUC	area under the curve
Cmax	maximum plasma concentration
KLF-2	Kruppel-like factor 2
HVPG	hepatic venous pressure gradient
NSBB	non-selective beta blocker
CK	creatinine kinase
ETOH	ethanol
ULN	upper limit of normal
NODM	new-onset diabetes mellitus
FDA	Food and Drug Administration
CYP	cytochrome P450
P-gp	P-glycoprotein
STAREE	STAtin Therapy for Reducing Events in the Elderly
DILI	drug-induced liver injury
CT	computed tomography
LFTs	liver function tests
1H-MRS	proton magnetic resonance spectroscopy
NAS	NAFLD activity score
FIB-4	Fibrosis 4 Index for Liver Fibrosis
IHCL	intrahepatocellular lipid
NAFLD	non-alcoholic fatty liver disease
MRI-PDFF	magnetic resonance imaging-derived proton density fat fraction
HCV	hepatitis C virus
HBV	hepatitis B virus
AIH	autoimmune hepatitis
BD	twice daily
PBC	primary biliary cholangitis
PON-1	paraoxanase-1, PPAR
PPAR-α	peroxisome proliferator-activated receptor alpha
FAO	fatty acid oxidation
eNOS	endothelial nitric oxide synthase
NO	nitric oxide
TNF-α	tumour necrosis factor alpha
IL-6	interleukin 6
TGF-β	transforming grown factor beta
LSEC	liver sinusoidal endothelial cell